Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Cannabidiol Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Cannabidiol Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Epidiolex (cannabidiol oral solution 100 mg/mL) for Boeing commercial members. It establishes initial-therapy, renewal, clinical indication, safety, specialist, and quantity-limit requirements for providers.

    Policy Summary
    PayerPrime Therapeutics
    PolicyCannabidiol Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required for Epidiolex; submit a qualifying indication, specialist involvement, non-monotherapy use for seizure management, and confirmation of no FDA-labeled contraindication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100 mg/mLEpidiolex strength
    1,000 mLQuantity limit per 30 days
    12 monthsApproval duration
    3Named seizure syndromes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10 bottles/30 days
    Quantity-limit example

    Coverage Criteria

    Initial evaluation

    Covered for initial therapy when ALL of the following are met.

    Initial therapy

    • Qualifying indication

      • Named seizure syndromes

        • The patient has seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
      • Other FDA-labeled indication

        • The patient has another FDA-labeled indication for the requested agent and route of administration.
        • Age requirement

          • The patient's age is within FDA labeling for the requested indication for the requested agent.
          • There is support for using the requested agent for the patient's age for the requested indication.
      • Compendia-supported indication

        • The patient has an indication supported in compendia for the requested agent and route of administration.AHFS or DrugDex evidence level 1, 2a, or 2b
    • Additional requirements

      • The requested agent will not be used as monotherapy for seizure management.
      • The prescriber is a specialist in the area of the patient's diagnosis, such as a neurologist, or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
      • The patient does not have any FDA-labeled contraindications to the requested agent.

    Renewal evaluation

    Covered for renewal when ALL of the following are met.

    Renewal therapy

    • The patient has been previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • The requested agent will not be used as monotherapy for seizure management.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as a neurologist, or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does not have any FDA-labeled contraindications to the requested agent.

    Quantity-limit evaluation

    The quantity limit is covered when ONE of the following is met.

    Quantity-limit approval

    • Within program limit

      • The requested quantity or dose does not exceed the program quantity limit.1,000 mL per 30 days
    • Qualifying exception

      • ONE qualifying exception

        • Higher dose without FDA maximum

          • The requested agent does not have a maximum FDA-labeled dose for the requested indication.

    Use of Epidiolex (cannabidiol oral solution) as monotherapy for seizure management is excluded from approval. For seizure-related treatment, it must be used with other therapy and not as the sole antiseizure treatment.

    Initial Therapy Criteria

    Initial evaluation

    Initial approval requires ALL applicable criteria.

    Initial cannabidiol therapy

    • Qualifying indication

      • Named seizure syndromes

        • The patient has seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
      • Other FDA-labeled indication

        • The patient has another FDA-labeled indication for the requested agent and route of administration.
        • Age requirement

    Continuation Criteria

    Renewal criteria

    Renewal approval requires ALL of the following.

    Continuation therapy

    • The patient has been previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • The requested agent will not be used as monotherapy for seizure management.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as a neurologist, or the prescriber has consulted with a specialist in the area of the patient's diagnosis.

    Quantity Limits

    Epidiolex Quantity Limit
    MedicationEpidiolex (cannabidiol oral solution 100 mg/mL)
    Program quantity limit1,000 mL
    Dispensing period30 days

    Quantity-Limit and Dose Calculation

    Epidiolex Quantity Limit
    Limit1,000 mL per 30 days
    Dose formOral solution measured in mL
    Strength100 mg/mL
    Quantity-Limit Calculation
    Weight and daily doseCDC 90th percentile for men: 125.1 kg × 25 mg/kg/day = 3,127.5 mg/day
    30-day dose3,127.5 mg/day × 30 days = 93,825 mg
    Volume conversion93,825 mg ÷ 100 mg/mL = 938.25 mL

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for cannabidiol when the patient has a qualifying indication and meets the applicable clinical criteria. Approval requires an FDA-labeled indication or a compendia-supported indication for the requested agent and route of administration.

    • Qualifying seizure diagnoses include Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
    • Other FDA-labeled indications must be for the requested agent and route of administration.
    • Compendia support must meet AHFS or DrugDex level 1, 2a, or 2b evidence.
    • For an FDA-labeled indication, the patient's age must be within labeling or there must be support for use at the patient's age.
    Prior Authorization

    Renewal Prior Authorization

    Renewal authorization requires prior approval and demonstrated clinical benefit. The requested agent must continue to satisfy the seizure-management, specialist-involvement, and safety requirements.

    Policy Background

    Cannabidiol oral solution is covered for qualifying seizure-related indications, including seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Coverage may also apply to another FDA-labeled indication for the requested agent and route of administration when applicable age requirements or supporting evidence are met, or to a compendia-supported indication. For seizure management, the agent must not be used as monotherapy; specialist involvement or consultation is also required, and FDA-labeled contraindications must be absent.

    Definitions and Supporting Standards

    Compendia Allowed
    Compendia sourcesAHFS or DrugDex
    Accepted evidence levelsLevel 1, 2a, or 2b
    UseSupports an indication for the requested agent and route of administration
    Program Quantity Limit
    DefinitionThe maximum quantity generally allowed under the program for the requested agent during the stated dispensing period
    Standard approval pathwayThe requested quantity does not exceed the program quantity limit
    Exception pathway
    Policy Summary
    PayerPrime Therapeutics
    PolicyCannabidiol Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required for Epidiolex; submit a qualifying indication, specialist involvement, non-monotherapy use for seizure management, and confirmation of no FDA-labeled contraindication.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaQuantity LimitsQuantity-Limit and Dose CalculationAuthorization and Documentation RequirementsPolicy BackgroundDefinitions and Supporting Standards
    There is support for therapy with a higher dose for the requested indication.
  1. Higher dose within FDA maximum

    • The requested quantity or dose does not exceed the maximum FDA-labeled dose for the requested indication.
    • There is support for why the requested quantity or dose cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
  2. The patient's age is within FDA labeling for the requested indication for the requested agent.
  3. There is support for using the requested agent for the patient's age for the requested indication.
  4. Compendia-supported indication

    • The patient has an indication supported in compendia for the requested agent and route of administration.AHFS or DrugDex evidence level 1, 2a, or 2b
  5. Additional requirements

    • The requested agent will not be used as monotherapy for seizure management.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as a neurologist, or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does not have any FDA-labeled contraindications to the requested agent.
  6. The patient does not have any FDA-labeled contraindications to the requested agent.
    Bottle rounding938.25 mL is rounded to 10 bottles per 30 days
  7. The patient must have been previously approved through the plan's Prior Authorization process; patients without prior approval require initial evaluation.
  8. The patient must have experienced clinical benefit with the requested agent.
  9. The agent must not be used as monotherapy for seizure management.
  10. The prescriber must be a specialist in the diagnosis area, such as a neurologist, or must have consulted with one.
  11. The patient must not have FDA-labeled contraindications to the requested agent.
  12. Documentation Required

    Initial Clinical Documentation

    Submit clinical documentation supporting the diagnosis, qualifying indication, patient-specific factors, and requested use. Documentation should establish that the requested agent and route are appropriate and that all initial criteria are met.

    • Document the diagnosis of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex, or document another FDA-labeled or compendia-supported indication.
    • For an FDA-labeled indication, document the patient's age and that the requested use is within labeling or supported for the patient's age.
    • Document that cannabidiol will not be used as monotherapy for seizure management.
    • Identify the prescribing specialist or document specialist consultation.
    • Document the absence of FDA-labeled contraindications.
    Documentation Required

    Renewal Documentation

    Renewal requests must document prior plan approval, ongoing clinical benefit, and continued appropriate use. Include evidence that specialist involvement, non-monotherapy use, and safety requirements remain satisfied.

    • Provide the prior authorization approval or otherwise establish that the patient was previously approved through the plan's process.
    • Document the patient's clinical benefit with the requested agent.
    • Identify the specialist prescriber or document consultation with a specialist in the diagnosis area.
    • Confirm that the agent is not being used as monotherapy for seizure management.
    • Confirm that the patient has no FDA-labeled contraindications.
    Documentation Required

    Quantity-Limit Exception Documentation

    When the requested quantity exceeds the program limit, provide documentation supporting the requested dose and the applicable exception. Approval requires evidence for the maximum dose or a rationale explaining why a lower quantity of a higher strength cannot be used.

    • State the requested quantity or dose.
    • If there is no maximum FDA-labeled dose for the indication, provide support for therapy at the higher dose.
    • If a maximum FDA-labeled dose exists, document that the requested quantity does not exceed it.
    • Explain why the requested quantity cannot be achieved with a lower quantity of a higher strength that remains within the program quantity limit.
    Denial Risk

    Failure to Meet Clinical or Safety Criteria

    The request may be denied when the clinical and safety requirements are not supported. Initial approval is not available for an unsupported indication, monotherapy use for seizure management, or a patient with an FDA-labeled contraindication.

    • The requested agent or route lacks an FDA-labeled or qualifying compendia-supported indication.
    • The requested agent will be used as monotherapy for seizure management.
    • The patient has an FDA-labeled contraindication to the requested agent.
    • Required age support for an FDA-labeled indication is not established.
    • Required specialist involvement is not established.
    Denial Risk

    Renewal Eligibility or Benefit Not Established

    A renewal request may be denied when prior approval or continued clinical benefit is not established. Renewal also requires continued compliance with the non-monotherapy, specialist, and safety criteria.

    • The patient was not previously approved through the plan's Prior Authorization process.
    • The patient has not demonstrated clinical benefit with the requested agent.
    • The requested agent will be used as monotherapy for seizure management.
    • Required specialist prescribing or consultation is not documented.
    • An FDA-labeled contraindication is present.
    Denial Risk

    Quantity Limit Exceeded Without Qualifying Exception

    A quantity-limit exception may be denied when the requested quantity exceeds the program limit without the required clinical support or rationale. Quantities within the program limit do not require an exception, but higher quantities must meet one of the qualifying pathways.

    • The requested quantity exceeds the program quantity limit and no qualifying exception is documented.
    • For an agent without a maximum FDA-labeled dose, support for therapy at the higher dose is missing.
    • For an agent with a maximum FDA-labeled dose, the requested quantity exceeds that maximum.
    • The request does not explain why a lower quantity of a higher strength within the program limit cannot achieve the prescribed dose.
    A quantity above the limit requires a qualifying documented exception